Preimplantation genetic screening outcomes are associated with culture conditions

Beyer, C; Osianlis, Tiki; Boekel, K.; Osborne, E; Rombauts, Luk; Catt, James; Kralevski, V.; Aali, Bibi Shahnaz; Gras, Lyn

doi:10.1093/humrep/den502

Cited by 19 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Beyer and colleagues showed an improvement in livebirth rates in women R40 years with less than two previous stimulated IVF cycles after changing embryo culture media after biopsy (168). Media become especially important in terms of pH buffering during the biopsy procedure.…”

Section: Embryo Biopsy Technique Is Important For Maintaining Embryo Qualitymentioning

confidence: 99%

Optimizing the culture environment and embryo manipulation to help maintain embryo developmental potential

Swain¹,

Carrell

Cobo

et al. 2016

Fertility and Sterility

View full text Add to dashboard Cite

With increased use of comprehensive chromosome screening (CCS), the question remains as to why some practices do not experience the same high levels of clinical success after implementation of the approach. Indeed, the debate surrounding the efficacy and usefulness of blastocyst biopsy and CCS continues. Importantly, several variables impact the success of an assisted reproductive technology cycle. Transfer of a euploid embryo is but one factor in an intricate system that requires numerous steps to occur successfully. Certainly, the culture environment and the manipulations of the embryo during its time in the laboratory can impact its reproductive potential. Environmental stressors ranging from culture media to culture conditions and even culture platform can impact biochemical, metabolic, and epigenetic patterns that can affect the developing cell independent of chromosome number. Furthermore, accompanying procedures, such as biopsy and vitrification, are complex and, when performed improperly, can negatively impact embryo quality. These are areas that likely still carry room for improvement within the IVF laboratory.

show abstract

Section: Embryo Biopsy Technique Is Important For Maintaining Embryo Qualitymentioning

confidence: 99%

Optimizing the culture environment and embryo manipulation to help maintain embryo developmental potential

Swain¹,

Carrell

Cobo

et al. 2016

Fertility and Sterility

View full text Add to dashboard Cite

show abstract

“…Studies ( 7 ) exploring the relationship between body mass index (BMI) and euploidy have yielded inconclusive results, and some degree of controversy remains. In addition, laboratory procedures, including culture conditions and blastocyst morphology, can affect the rate of aneuploidy ( 8 , 9 ).…”

Section: Introductionmentioning

confidence: 99%

Analysis of the Number of Euploid Embryos in Preimplantation Genetic Testing Cycles With Early-Follicular Phase Long-Acting Gonadotropin-Releasing Hormone Agonist Long Protocol

Niu

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

Studies have shown that early-follicular phase long-acting gonadotropin-releasing hormone (GnRH) agonist long protocol (EFLL), a popular controlled ovarian hyperstimulation protocol widely used in China, leads to higher rates of implantation and clinical pregnancy, as well as lower rates of spontaneous abortion and ectopic pregnancy in patients undergoing in vitro fertilization treatment. However, the impact of EFLL on euploid embryos and its underlying mechanisms remain unclear. To address these gaps of knowledge, we conducted a retrospective comparative study of 310 preimplantation genetic testing (PGT) cycles with a total of 1,541 embryos using the EFLL protocol or midluteal short-acting GnRH agonist long protocol (MLSL). Patients were matched by PGT subtype [aneuploidies (PGT-A) vs. PGT for chromosomal structural rearrangements (PGT-SR)], age (±2 years), and body mass index (±1 kg/m 2 ). For PGT-A, there was no significant difference in the number of euploid embryos (1.80 ± 1.47 for EFLL vs. 1.84 ± 2.03 for MLSL, p > 0.05) or the rate of euploidy (44.6 vs. 36.9%, p > 0.05). For PGT-SR, the number of euploid embryos in the EFLL group was significantly higher than that in the MLSL group (1.76 ± 1.54 vs. 1.21 ± 1.24, p < 0.05). A higher euploidy rate was also observed with the EFLL protocol compared with that obtained in MLSL (31.9 vs. 25.7%), although the difference was not statistically significant ( p > 0.05). Compared with the MLSL protocol, more euploid embryos were achieved when using the EFLL protocol in PGT-SR, demonstrating the value in PGT-SR. To the best of our knowledge, this study is the first one to compare embryonic outcomes between EFLL and MLSL, providing key insights into the clinical application of EFLL in PGT cycles. In the light of the limited sample size of our study, we recommend that these questions be explored using a larger prospective study.

show abstract

“…In addition, early reports described that LH-containing gonadotropins may improve embryonic euploidy compared with pure FSH stimulation, but this has not been further corroborated (8,9). Moreover, it has been reported that laboratory conditions can affect pregnancy rates (10,11). It is worth noting many of these studies were performed using older PGT-A techniques, mainly with fluorescent in situ hybridization, but there is a lack of data using more sensitive modalities, including nextgeneration sequencing (NGS) (7)(8)(9)(10)(11).…”

mentioning

confidence: 99%

Euploidy rates between cycles triggered with gonadotropin-releasing hormone agonist and human chorionic gonadotropin

Thorne

Loza

Kaye

et al. 2019

Fertility and Sterility

View full text Add to dashboard Cite

Objective: To evaluate differences in euploidy rates between IVF cycles triggered with either GnRH agonist (GnRHa) or hCG. Design: Retrospective cohort study. Setting: University-affiliated fertility center. Patient(s): A total of 366 patients performing 539 IVF cycles utilizing preimplantation genetic testing for aneuploidy (PGT-A). Intervention(s): Gonadotropin-releasing hormone agonist or hCG trigger of oocyte maturation during IVF cycles. Main Outcome Measure(s): Rate of euploid embryos. Result(s): Patients in the GnRHa trigger arm were younger, with a lower body mass index and higher antim€ ullerian hormone level, and they had a higher number of oocytes retrieved and embryos biopsied. Euploid rate per embryo biopsied was higher after GnRHa trigger than after hCG trigger (37.8% AE 2.1% vs. 30.3% AE 1.8%), but multivariate regression analysis controlling for potential confounding factors did not show any differences between the two groups. Moreover, the euploid rate per oocyte retrieved was not significantly different overall (GnRHa vs. hCG: 33.9% AE 2.2% vs. 28.0% AE 1.9%). The anticipated decline in the rate of euploid embryos per oocyte retrieved went from 15.8% AE 1.2% for age <35 years to 4.3% AE 0.9% for patients aged R41 years. There were no significant differences between the two groups after stratifying by age and controlling for PGT-A testing modality. Conclusion(s): Both GnRHa and hCG trigger result in comparable euploid rates. Trigger with GnRHa should therefore be considered a valid option for trigger modality in freeze-all PGT-A cycles, in view of its demonstrated effectiveness and known safety enhancement. (Fertil Steril Ò 2019;112:258-65. Ó2019 by American Society for Reproductive Medicine.) El resumen está disponible en Español al final del artículo.

show abstract

Preimplantation genetic screening outcomes are associated with culture conditions

Abstract: These results suggest that a laboratory procedure change may significantly impact PGS patient outcomes.

Cited by 19 publications

References 26 publications

Optimizing the culture environment and embryo manipulation to help maintain embryo developmental potential

Optimizing the culture environment and embryo manipulation to help maintain embryo developmental potential

Analysis of the Number of Euploid Embryos in Preimplantation Genetic Testing Cycles With Early-Follicular Phase Long-Acting Gonadotropin-Releasing Hormone Agonist Long Protocol

Euploidy rates between cycles triggered with gonadotropin-releasing hormone agonist and human chorionic gonadotropin

Contact Info

Product

Resources

About